Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell ...

Radiopharmaceuticals-focused Artbio has drawn in a $132 million series B to push its lead prostate cancer prospect through ...

Veteran clinical research leader Melissa Holbrook has found her next permanent role. | Veteran clinical research leader ...

Quoin Pharmaceuticals has ended development of two programs, pulling back from the assets as it starts to gear up for the ...

Bausch Health has struck a deal to buy Durect for $63 million upfront, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.

As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.

After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

Having recently scored approval for Nucala in chronic obstructive pulmonary disease (COPD), GSK has now signed a major ...

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for ...

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...